VIM and breast carcinoma: Treatment with SMRwt of MDA-MB-231 and MCF-7 breast cancer cells lowered the protein expression of Mortalin to 27.66% and 60% as well as Vimentin to 14.12% and 23.68% (Fig. 5A).